India’s pharmaceutical sector is witnessing a significant development as Eris Lifesciences and Natco Pharma have introduced a generic version of Semaglutide, a widely used treatment for Type 2 Diabetes. The launch could improve affordability and access to advanced diabetes therapies across the country. Semaglutide-based medicines have gained global attention not only for managing blood glucose levels but also for their role in weight management.